预约演示
更新于：2025-01-21
Fluocinolone Acetonide/Hydroquinone/Tretinoin
氟轻松丙酮酯/氢醌/维A酸
更新于：2025-01-21
概要
基本信息
药物类型 小分子化药 |
别名 Hydroquinone/tretinoin/fluocinolone-acetonide、Tri-Luma |
作用机制 GR激动剂(糖皮质激素受体激动剂)、RARα激动剂(维甲酸受体α激动剂)、RARβ2激动剂(维甲酸受体β激动剂) |
在研适应症 |
非在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-01-18), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H30F2O6 |
InChIKeyFEBLZLNTKCEFIT-VSXGLTOVSA-N |
CAS号67-73-2 |
查看全部结构式(3)
关联
7
项与 氟轻松丙酮酯/氢醌/维A酸 相关的临床试验CTR20200866
多中心、随机、双盲、三臂、平行、安慰剂对照临床试验评价维氟醌乳膏治疗中、重度黄褐斑的疗效和安全性
CTRI/2018/01/011403
Evaluation of â??Quality of Lifeâ?? and in-use tolerance in women with facial melasma, after using a triple combination drug (TRI-LUMA Cream)
NCT01778179
Safety and Efficacy of a Triple Combination Cream as Adjuvant Treatment of Solar Lentigines With Cryotherapy.
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的临床结果
登录后查看更多信息
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的转化医学
登录后查看更多信息
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的专利（医药）
登录后查看更多信息
26
项与 氟轻松丙酮酯/氢醌/维A酸 相关的文献（医药）2024-09-01Journal of surgical oncology
Does Tri‐Staple™ technology reduce the risk of anastomotic leakage in colorectal surgery? A propensity score matching analysis
Article
作者: Araujo, Sergio Eduardo Alonso ; Seid, Victor Edmond ; Gerbasi, Lucas Soares ; Tustumi, Francisco
Abstract:
Background and Objectives:
This study evaluates the Tri‐Staple™ technology in colorectal anastomosis.
Methods:
Patients who underwent rectosigmoidectomy between 2016 and 2022 were retrospectively evaluated and divided into two groups: EEA™ (EEA) or Tri‐Staple™ (Tri‐EEA). The groups were matched for age, sex, American Society of Anesthesiologists (ASA), and neoadjuvant radiotherapy using propensity score matching (PSM).
Result:
Three hundred and thirty‐six patients were included (228 EEA; 108 Tri‐EEA). The groups were similar in sex, age, and neoadjuvant therapy. The Tri‐EEA group had fewer patients with ASA III/IV scores (7% vs. 33%; p < 0.001). The Tri‐EEA group had a lower incidence of leakage (4% vs. 11%; p = 0.023), reoperations (4% vs. 12%; p = 0.016), and severe complications (6% vs. 14%; p = 0.026). There was no difference in complications, mortality, readmission, and length of stay. After PSM, 108 patients in the EEA group were compared with 108 in the Tri‐EEA group. The covariates sex, age, neoadjuvant radiotherapy, and ASA were balanced, and the risk of leakage (4% vs. 12%; p = 0.04), reoperation (4% vs. 14%; p = 0.014), and severe complications (6% vs. 15%; p = 0.041) remained lower in the Tri‐EEA group.
Conclusion:
Tri‐Staple™ reduces the risk of leakage in colorectal anastomosis. However, this study provides only insights, and further research is warranted to confirm these findings.
2022-03-01Food chemistry1区 · 农林科学
The inhibition of pectin oligosaccharides on degranulation of RBL-2H3 cells from apple pectin with high hydrostatic pressure assisted enzyme treatment
1区 · 农林科学
Article
作者: Wang, Yu ; Gao, Zhenpeng ; Yue, Tianli ; Long, Fangyu ; Ma, Jing ; Ren, Hong ; Tong, Pengyan ; Chen, Yajing
The conditions for the preparation of pectic oligosaccharides (POS) by high hydrostatic pressure-assisted enzymatic (E-HHP) method were explored. The optimal conditions consisted of the pressure of 350 MPa for 20 min, and enzymolysis for 60 min with 0.011 U/mL enzyme. The products were isolated by ion exchange chromatography, galacturonic acid, di- and tri-galacturonides (Tri-GalA) with high purity were obtained. Additionally, the effects of POS on activation and degranulation of RBL-2H3 mast cells were investigated. It was found that Tri-GalA and POS could attenuate the release of β-hexosaminidase and histamine, reduce the production of IL-4 and inhibit the extracellular Ca2+ influx of RBL-2H3 cells. Notably, 150 μg/mL POS significantly alleviated the IgE-mediated allergic reaction of RBL-2H3 cells. These results indicate that POS could be used as an inhibitor in regulating mast cell-mediated allergic inflammatory responses.
2021-07-01Veterinary parasitology, regional studies and reports
Efficacy of a single administration of afoxolaner (NexGard®) or fipronil plus permethrin (Frontline® Tri-Act) against Hyalomma marginatum ticks in dogs
Article
作者: Akki, Fatima Ezzahra ; Beugnet, Fréderic ; Madder, Maxime ; Lebon, Wilfried ; Meyer, Leon
This study was conducted to assess the acaricidal efficacy of afoxolaner (NexGard®, Boehringer Ingelheim), and fipronil - permethrin (Frontline® Tri-Act, Boehringer Ingelheim) administered once to dogs experimentally infested with Hyalomma marginatum ticks. Twenty-four Beagle dogs were randomly allocated based on a pre-treatment H. marginatum infestation to an untreated control group, a NexGard® or a Frontline® Tri-Act treated groups. Treatments were administered once on Day 0 as per the products' labels. For the efficacy evaluation, dogs were experimentally infested with 30 adult H. marginatum ticks on Days -2, 7, 28 and 36. In-situ counts were performed at 48 h post-treatment on Day 2 and post-infestations on Days 9, 30 and 38. Ticks were removed and counted at 72 h post-treatment on Day 3 and after each tick infestation on Days 10, 31 and 39. The numbers of live ticks counted in the treated groups were significantly different than in the control group at all time-points (p ≤ 0.0006). The efficacy was at least 97% after 48 h, and at least 99% after 72 h for both treatments. In this study both afoxolaner and fipronil/permethrin formulations demonstrated a high efficacy against adult H. marginatum ticks in treated dogs for at least five weeks.
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 黄褐斑 | 美国 | 2002-01-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 雀斑样痣 | 临床2期 | 智利 | - | 2008-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 50 | Cryotherapy (CRY-AC3® device)+Tri-luma (Group 1) | 壓艱遞遞餘襯鑰鏇鏇膚(衊鏇艱襯顧觸繭憲窪網) = 艱鬱襯願鹽窪遞顧繭鹹 範淵壓醖糧憲廠廠獵觸 (夢壓壓鑰蓋衊衊衊觸觸, 觸蓋積鹽壓觸鏇襯獵淵 ~ 衊衊積簾齋艱築鏇淵鏇) 更多 | - | 2020-09-17 | ||
Cryotherapy (CRY-AC3® device) (Group 2) | 壓艱遞遞餘襯鑰鏇鏇膚(衊鏇艱襯顧觸繭憲窪網) = 觸壓糧製醖憲鑰襯鹹製 範淵壓醖糧憲廠廠獵觸 (夢壓壓鑰蓋衊衊衊觸觸, 鬱鏇襯繭獵構鹽窪選築 ~ 艱蓋壓廠製簾積顧襯築) 更多 | ||||||
临床4期 | 56 | (Intense Pulsed Light (IPL) / Tri-Luma® Cream) | 鏇顧鹹蓋鏇築艱顧蓋衊(淵鏇鬱淵鬱壓糧膚選鹽) = 餘壓衊餘獵窪壓構夢襯 齋範構構夢遞觸遞範簾 (積鹽鏇願觸觸淵窪網夢, 築鏇鬱夢醖鬱廠蓋鏇製 ~ 獵蓋襯夢餘鬱衊壓範鏇) 更多 | - | 2010-01-11 | ||
Cetaphil (Intense Pulsed Light (IPL) / Inactive Control Cream) | 鏇顧鹹蓋鏇築艱顧蓋衊(淵鏇鬱淵鬱壓糧膚選鹽) = 觸構鹹憲壓積憲夢製築 齋範構構夢遞觸遞範簾 (積鹽鏇願觸觸淵窪網夢, 築廠鏇衊遞鏇餘夢築網 ~ 膚窪繭糧壓衊鏇構壓淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用